Seven Bridges’ Biomedical Data Analysis Platform First to be Available in Multi- and Hybrid Cloud Environments

CAMBRIDGE, Mass.–(BUSINESS WIRE)–January 19, 2016–

Seven Bridges, the biomedical data analysis company, today announced that its cloud-based platform for large-scale genomic discovery is now deployed on Google Cloud Platform. The Seven Bridges Platform is the first such system to be available on multiple public cloud infrastructures. By offering flexible deployment options, Seven Bridges empowers research enterprises to run a wide variety of “gold standard” and custom analysis workflows on their computational environment of choice, whether Google Cloud Platform (GCP), Amazon Web Services (AWS) or other public or private infrastructures.

“The Seven Bridges Platform gives researchers the freedom to choose the best infrastructure for the task at hand, and makes it easy to access Google-hosted tools and data,” said Dr. Deniz Kural, CEO of Seven Bridges. “Because the Platform sits on multiple infrastructures it is the enabling technology needed to make reproducible analyses in multiple locations as simple as a copy-and-paste.”

“We’re excited to welcome users of Seven Bridges Platform to our cloud,” said David Glazer, Director of Engineering for Google Genomics. “Seven Bridges makes it easy and fast for bioinformaticians and biologists to take advantage of our scalable and secure infrastructure, and our standards-compliant genomics services. We’re looking forward to seeing users build on our complementary strengths to accelerate research and progress in precision medicine.”

The Seven Bridges Platform provides a scalable, secure and flexible suite of tools for the consistent, collaborative analysis of biomedical data. The Platform offers many of the most popular bioinformatics pipelines, to help scientists quickly get to work on standard analytic workflows. It also includes an award-winning pipeline builder and an extensive API and SDK, for when complete customization is needed.

“Around the world, we are seeing ever-larger genomics projects, generating ever-more informative data for researchers,” said James Sietstra, President of Seven Bridges. “With its flexibility to run on multiple clouds and hybrid infrastructures, the Seven Bridges Platform can help new projects get up and running quickly. It also supports the continued growth of the national projects we already collaborate with, including the Cancer Genomics Cloud and the 100,000 Genomes Project.”

Learn more at www.sevenbridges.com/infrastructure

About Seven Bridges
Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including two of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to the world’s largest cancer genomics dataset. The company’s 187 experts work from its Cambridge, MA headquarters and offices in Belgrade, London and San Francisco.

Seven Bridges
Amanda Orr, +1-202-459-1304
or
Laurie Gibson, +1-650-815-1438